TScan Therapeutics, Inc.
TCRX
$0.95
-$0.07-6.65%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -18.37% | 41.69% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -18.37% | 41.69% | |||
| Cost of Revenue | -2.90% | 9.55% | |||
| Gross Profit | 1.29% | -7.03% | |||
| SG&A Expenses | -13.42% | 5.35% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.19% | 8.61% | |||
| Operating Income | 4.14% | -6.63% | |||
| Income Before Tax | 3.36% | -8.28% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 3.36% | -8.28% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 3.36% | -8.28% | |||
| EBIT | 4.14% | -6.63% | |||
| EBITDA | 4.40% | -6.70% | |||
| EPS Basic | 3.36% | -7.98% | |||
| Normalized Basic EPS | 3.37% | -7.99% | |||
| EPS Diluted | 3.36% | -7.98% | |||
| Normalized Diluted EPS | 3.37% | -7.99% | |||
| Average Basic Shares Outstanding | 0.00% | 0.28% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.28% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||